KCT0000052招募中未知
Multi-center, Randomized, Open label Study of the Durability of glycemic control with Nateglinide versus Glimepiride as monotherapy in type 2 diabetic patients
Ajou University Hospital0 个研究点目标入组 200 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •‣ Type 2 diabetes mellitus
- •‣ Age >=18 years
- •‣ No anti-hyperglycemic agent for 3 months or low-dose oral hypoglycemic therapy
- •⁃ Metformin <_1g/day
- •⁃ Acarbose <_300mg/day
- •⁃ Voglibose <_0.9mg/day
- •⁃ Nateglinide <_270mg/day
- •⁃ Gliclazide <_80mg/day
- •⁃ Glimepiride <_2mg/day
- •⁃ Glibenclamide <_5mg/day
- •‣ 6.5% <_ HbA1c <_8.5%
- •‣ patients on no anti hyperglycemic agent for 3 months: HbA1c at screening
- •‣ patients on oral hypoglycemic therapy in 3 months: HbA1c after wash-out
排除标准
- •‣ attending other clinical trails in 3 months
- •‣ type 1 diabetes mellitus
- •‣ taking systemic steroid in 1months or requiring steroid therapy during clincal trial
- •‣ acute myocaldial infacrtion in 6 months
- •‣ alcoholics, pituitary or adrenal insufficiency, severe ketosis, diabetic ketoacidosis
- •‣ severe liver disease or AST, ALT >_ 2,5 * ULM
- •‣ renal insufficiency (serum creatinine > 2.0 mg/dl)
- •‣ other severe diabetic complication
- •‣ drug hypersensitivity history to nateglinide or sulfonylurea
- •‣ pregnant or plan to becom pregnant during the cliniclatrial, lactation
研究者
相似试验
进行中（未招募）
1 期
A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, andImmunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in HealthyAdolescents 11-17 Years of Age.Prevention of Human Papillomavirus InfectionMedDRA version: 7.0Level: LLTClassification code 10063001EUCTR2006-000764-85-BEMerck Sharp & Dohme BV800
进行中（未招募）
不适用
A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, andImmunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in HealthyAdolescents 11-17 Years of AgeEUCTR2006-000764-85-DEMerck & Co., Inc800
进行中（未招募）
不适用
A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, andImmunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in HealthyAdolescents 11-17 Years of AgeEUCTR2006-000764-85-FIMerck & Co., Inc800
进行中（未招募）
不适用
A Open-label, Randomized, Multicenter Study of the Safety, Tolerability, andImmunogenicity of GARDASIL™ Given Concomitantly with REPEVAX™ in HealthyAdolescents 11-17 Years of AgePrevention of Human Papillomavirus InfectionMedDRA version: 7.0Level: LLTClassification code 10063001EUCTR2006-000764-85-DKMerck & Co. Inc.800
进行中（未招募）
不适用
A study of the safety, efficacy, and tolerability of combination treatment of setrobuvir, danoprevir, ritonavir, and Copegus® with or without mericitabine in patients infected with the Hepatitis C virus who never received treatment beforeEUCTR2012-000638-21-PLF. Hoffmann-La Roche Ltd110